Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Insulin: Dosing Regimen and Adverse Effects01:16

Insulin: Dosing Regimen and Adverse Effects

Insulin-replacement therapy usually includes both long-acting insulin (basal) and short-acting insulin (to cater to postprandial needs). In a diverse group of type 1 diabetes patients, the average daily insulin dose is typically 0.5-0.7 units/kg body weight. However, obese patients and pubertal adolescents may need more due to insulin resistance.
The basal dose constitutes about 40%-50% of the total daily dose, with the rest as premeal insulin. The mealtime insulin dose should mirror...
Glucagon-like Receptor Agonists01:24

Glucagon-like Receptor Agonists

Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by the...
Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
Oral Hypoglycemic Agents: Glinides01:06

Oral Hypoglycemic Agents: Glinides

Repaglinide (Prandin) and Nateglinide (Starlix), known as glinides, are oral insulin secretagogues that stimulate insulin release from pancreatic β cells by closing the ATP-sensitive potassium channels (KATP channel). Repaglinide controls insulin release from pancreatic β cells by managing potassium efflux. It shares two binding sites with sulfonylureas and also has a unique site, indicating overlapping mechanisms of action. With a rapid onset and a 4-7 hour duration, it effectively manages...
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Prevalence and biopsychosocial factors associated with overweight and obesity in adults with type 1 diabetes.

International journal of obesity (2005)·2026
Same author

Increased Glycation Ratio and Risk of Complications in Latent Autoimmune Diabetes in Adults Compared With Type 1 Diabetes Onset before 30 Years: A Cohort Study.

Diabetes technology & therapeutics·2026
Same author

Long-term Air Pollution and Overall and Regional Body Composition in Older Adults With Overweight or Obesity and Metabolic Syndrome.

Diabetes care·2026
Same author

International expert consensus on definitions and management of weight recurrence and suboptimal response after metabolic and bariatric surgery: a Delphi study.

Surgery for obesity and related diseases : official journal of the American Society for Bariatric Surgery·2026
Same author

Understanding the experience of women living with obesity and reproductive pathology.

Endocrinologia, diabetes y nutricion·2026
Same author

Inpatient safety, effectiveness of SGLT2 inhibitors and GLP-1 RAs in type 2 diabetes: ENDOCARE, a pragmatic prospective cohort study.

Cardiovascular diabetology·2026
Same journal

Correction: Low-Dose Naltrexone: What is the Evidence? A Narrative Review.

Advances in therapy·2026
Same journal

Usability and Acceptance of Autoinjector and Prefilled Syringe Devices by Patients with Generalized Myasthenia Gravis in a Human Factors Study.

Advances in therapy·2026
Same journal

Treatment Patterns and Decision Drivers in Chinese Patients with Locally Advanced Cervical Cancer: Results from a National Physician Survey.

Advances in therapy·2026
Same journal

Matching-Adjusted Indirect Comparison of Tarlatamab for Patients with Platinum-Refractory or Platinum-Resistant Extensive-Stage Small-Cell Lung Cancer.

Advances in therapy·2026
Same journal

Sacral Neuromodulation for Refractory Overactive Bladder: Closing the Gaps in Anatomy, Mechanisms, and Parameter Selection.

Advances in therapy·2026
Same journal

Exploring the Impact of Delivering Allergy Medication as Self-Care on Healthcare Greenhouse Gas Emissions in the United Kingdom.

Advances in therapy·2026
See all related articles

Related Experiment Video

Updated: Jun 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Once-Weekly Subcutaneous Semaglutide 2.4 mg Injection is Cost-Effective for Weight Management in Spain.

Andreu Altés1, Óscar Moreno-Pérez2,3, Miquel Sastre-Belío4

  • 1Family Medicine, Sants Primary Care Center, Barcelona, Spain.

Advances in Therapy
|June 6, 2026
PubMed
Summary
This summary is machine-generated.

Subcutaneous semaglutide 2.4 mg, combined with diet and exercise, is a cost-effective obesity treatment in Spain. This approach offers improved health outcomes compared to diet and exercise alone, supporting national health systems.

Keywords:
Cost-effectiveness analysisEconomic impactObesitySemaglutide 2.4 mgSpainWeight loss

More Related Videos

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Related Experiment Videos

Last Updated: Jun 7, 2026

Multidisciplinary Approach to Obesity Management: A Case Report
05:10

Multidisciplinary Approach to Obesity Management: A Case Report

Published on: May 30, 2025

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices
06:34

Validation of Therapeutic Agent Conjugation to Polyvinyl Alcohol-Coated Medical Devices

Published on: November 29, 2024

Area of Science:

  • Pharmacoeconomics
  • Obesity Management
  • Public Health

Background:

  • Rising obesity rates pose a significant challenge to national health systems.
  • Subcutaneous semaglutide 2.4 mg is approved for obesity treatment alongside diet and exercise (D&E).

Purpose of the Study:

  • To evaluate the cost-effectiveness of semaglutide 2.4 mg plus D&E versus D&E alone for obesity treatment in Spain.

Main Methods:

  • A Markov state transition model (Core Obesity Model v26) projected outcomes over 40 years.
  • Data from the STEP 1 trial informed efficacy, safety, BMI, blood pressure, and glycaemic status.
  • Analysis from the Spanish National Health System perspective included direct healthcare costs and QALYs.

Main Results:

  • Semaglutide 2.4 mg plus D&E yielded an additional 0.1049 QALYs at an increased cost of €2685 over 40 years.
  • The incremental cost-effectiveness ratio was €25,589 per QALY gained.
  • Semaglutide 2.4 mg was deemed cost-effective, falling below the €30,000/QALY threshold, with robust findings confirmed by sensitivity analyses.

Conclusions:

  • Semaglutide 2.4 mg combined with D&E is a cost-effective therapeutic option for adults with obesity in Spain.
  • This finding provides valuable data for optimizing healthcare decision-making regarding obesity treatment.